LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
News update: Leading Australian medical experts are driving public awareness and conversation about the increased severity and prevalence of sexual issues in men aged 65+, with a focus on Erectile Dysfunction (ED). Men in their 40’s have about a 40% chance of experiencing some form of ED, with prevalence increasing
Edison has released a report on LTR Pharma, highlighting the clinical validation of SPONTAN as a fast-acting intranasal treatment for erectile dysfunction and its progression toward regulatory submission. The report also covers our platform expansion into new markets through ROXUS and OROFLOW, alongside portfolio diversification via our recent investment in
LTR Pharma has announced that it has increased its ownership in LevOmega Pty Ltd from 33% to approximately 43%. Through its wholly owned subsidiary, LTR Spectrum Pty Ltd, LTR Pharma has invested A$1.0 million to support the advancement of LevOmega’s research and development programs. LevOmega was co-founded by LTR Pharma,
SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.